We are live on !
Find out more
SL
Siren LLC Portfolio holdings
AUM
$4.94B
Turnover
27.78%
1-Year Est. Return
244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
(+37%)
Cap. Flow
+$314M
Cap. Flow % of AUM
Cap. Flow %
6.35%
Top 10 Holdings %
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$82.7M |
| 2 |
Abivax
ABVX
|
+$65.2M |
| 3 |
Hemab Therapeutics
COAG
|
+$57.6M |
| 4 |
Relay Therapeutics
RLAY
|
+$53M |
| 5 |
Kailera Therapeutics
KLRA
|
+$48.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$60.4M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$42.9M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$41.8M |
| 4 |
Revolution Medicines
RVMD
|
+$30.8M |
| 5 |
Kymera Therapeutics
KYMR
|
+$21.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.94% |
| 2 | Technology | 3.57% |
| 3 | Communication Services | 1.85% |
| 4 | Financials | 0.87% |
| 5 | Consumer Discretionary | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Iris Energy
IREN
$8.4B
| $8M | 0.16% |
175,000
+131,900
| +306% | +$6.86M |
2025 Q3
3 quarters
|
|
77
Amazon
AMZN
$2.83T
| $7.75M | 0.16% |
32,500
-14,141
| -30% | -$3.55M |
2024 Q3
7 quarters
|
|
78
CrowdStrike
CRWD
$224B
| $7.63M | 0.15% |
40,000
-52,280
| -57% | -$7.43M |
2024 Q3
7 quarters
|
|
79
Design Therapeutics
DSGN
$643M
| $7.57M | 0.15% |
+523,212
| New | +$6.52M |
2026 Q2
0 quarters
|
|
80
Pinduoduo
PDD
$119B
| $7.25M | 0.15% |
95,000
+11,599
| +14% | +$1.07M |
2024 Q3
7 quarters
|
|
81
Satellos Bioscience
MSLE
$147M
| $6.94M | 0.14% |
892,074
| – | – |
2026 Q1
1 quarter
|
|
82
Dynatrace
DT
$12.4B
| $6.81M | 0.14% |
155,000
+5,000
| +3% | +$195K |
2024 Q3
7 quarters
|
|
83
CALL
Apple
AAPL
$4.99T
| $6.66M | 0.13% |
+23,000
| New | +$6.58M |
2026 Q2
0 quarters
|
|
84
Tenax Therapeutics
TENX
$63.2M
| $6.21M | 0.13% |
427,141
| – | – |
2025 Q3
3 quarters
|
|
85
vTv Therapeutics
VTVT
$84.6M
| $6.14M | 0.12% |
163,000
| – | – |
2025 Q3
3 quarters
|
|
86
Eloxx Pharmaceuticals
ELOX
$50.4M
| $5.55M | 0.11% |
+400,000
| New | +$5.1M |
2026 Q2
0 quarters
|
|
87
AgomAb Therapeutics NV
AGMB
$398M
| $5.34M | 0.11% |
411,250
| – | – |
2026 Q1
1 quarter
|
|
88
Alibaba
BABA
$271B
| $4.8M | 0.1% |
+50,000
| New | +$6.26M |
2026 Q2
0 quarters
|
|
89
Korro Bio
KRRO
$224M
| $4.58M | 0.09% |
347,718
| – | – |
2024 Q3
7 quarters
|
|
90
Cellebrite
CLBT
$3.11B
| $4.55M | 0.09% |
311,544
| – | – |
2025 Q2
4 quarters
|
|
91
Invivyd
IVVD
$171M
| $4.36M | 0.09% |
5,000,000
+1,000,000
| +25% | +$1.25M |
2025 Q4
2 quarters
|
|
92
Ouster
OUST
$2.39B
| $4.22M | 0.09% |
+67,500
| New | +$2.27M |
2026 Q2
0 quarters
|
|
93
Palisade Bio
PALI
$202M
| $4.18M | 0.08% |
+2,000,000
| New | +$3.94M |
2026 Q2
0 quarters
|
|
94
Aeva Technologies
AEVA
$716M
| $4.18M | 0.08% |
145,459
+35,459
| +32% | +$698K |
2026 Q1
1 quarter
|
|
95
Seer Inc
SEER
$92.5M
| $4.08M | 0.08% |
2,458,673
| – | – |
2024 Q3
7 quarters
|
|
96
NovaBridge Biosciences American Depositary Shares
NBP
$104M
| $3.91M | 0.08% |
2,004,739
-995,261
| -33% | -$2.03M |
2025 Q3
3 quarters
|
|
97
GitLab
GTLB
$7.93B
| $3.82M | 0.08% |
125,000
+25,000
| +25% | +$634K |
2025 Q2
4 quarters
|
|
98
Odyssey Therapeutics
ODTX
$947M
| $3.74M | 0.08% |
+200,000
| New | +$3.51M |
2026 Q2
0 quarters
|
|
99
Foghorn Therapeutics
FHTX
$112M
| $3.52M | 0.07% |
720,720
| – | – |
2024 Q3
7 quarters
|
|
100
Agenus
AGEN
$322M
| $3.26M | 0.07% |
1,064,250
| – | – |
2025 Q1
5 quarters
|
|
Similar funds
Siren LLC's Q2 2026 Portfolio in Review
As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.
- Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
- Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
- Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
- Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
- Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
- Siren LLC opened 26 new positions and closed 9 in Q2 2026.
- Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.
Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.